Biovie's Long COVID Trial Missed Its Big Moment — Can Subgroup Data Alone Justify What Comes Next?

Shares of BioVie Inc. jumped 10.8% to $1.33 as the micro-cap biotech presented Phase 2 data from its Long COVID trial at the American Neurological Association meeting in San Diego. But behind the headline pop lies a familiar biotech tension: the study didn't hit its mark in the full patient group, and the encouraging signals came from slicing the data into subsets — a far weaker form of evidence.

The Trial Failed on Its Broadest Measure. The study did not achieve statistical significance on any endpoint in the overall intent-to-treat population of 203 patients. BioVie attributed this to patients with low baseline symptom burden having little room to improve, which may have diluted the overall signal. In drug development, a missed overall population result is a serious setback — regulators at the FDA typically want to see a drug work across the broad group it's meant to treat, not just in cherry-picked slices.

Subgroup Wins Sound Good but Carry a Big Asterisk. In pre-specified subgroup analyses submitted to the FDA prior to data unblinding, patients with greater baseline symptom burden — representing approximately 78% of trial participants — demonstrated statistically significant improvements on multiple endpoints.

Among the most fatigued half, fatigue scores improved 8.93 points versus 5.30 with placebo (p=0.02). That's real, but subgroup analyses are hypothesis-generating and may not be replicated in future trials. BioVie needs a larger, confirmatory Phase 3 study to prove these effects hold up.

The Cash Clock Is Ticking. As of June 30, 2026, BioVie had just $9.0 million in cash , while burning roughly $19.0 million annually in operating cash. That suggests approximately five months of runway — a razor-thin margin for a company pursuing multiple clinical programs. A $13.13 million U.S. government award fully funds the Long COVID study , but BioVie also runs Alzheimer's and Parkinson's trials. The company acknowledges its viability "is largely dependent upon its ability to raise additional capital." At a market cap near $10 million, any equity raise would severely dilute existing shareholders.

No Approved Treatments Creates Opportunity — and Competition. Eight Phase 2 trials by various organizations have tested 13 interventions in Long COVID, and none have demonstrated benefit thus far. That gives BioVie a first-mover narrative in a market affecting an estimated 17–20 million U.S. adults. But a narrative without a clean trial win is a fragile thing to bet a stock on.